GAOMA Therapeutics

GAOMA develops new therapeutic molecules for neurological and inflammatory disorders, with a particular focus on epilepsy and cognitive disorders.

With 70 million people in the world, epilepsy is the most common severe neurological condition. This disease triggers seizures in patients, a phenomenon well known to the general public, but also various other disorders, such as cognitive impairment.

Existing anti-epileptic drugs have relatively similar mechanisms of action, with the only objective to disable neuronal activity. These drugs unfortunately leave a high unmet medical need: they are symptomatic treatments addressing seizures only, with a limited efficacy (one third of patients is drug resistant), and with a bad tolerance (side effects among a majority of patients).

GAOMA's lead drug candidate, named GAO-3-02, is a novel patented active ingredient. This derivative of a very long chain fatty acid has a truly innovative mechanism of action for the treatment of epilepsy. In various preclinical experiments, GAO-3-02 has thus demonstrated its ability to limit seizures, protect and restore cognitive functions, on the long term, and with a good tolerance.

Given GAO-3-02's mechanism of action, GAOMA will explore soon the potential efficacy of the molecule in other indications too.